An assessment of new cholesterol targets. Measuring Lp(a): A ‘once in a lifetime’ opportunity

This site is intended for UK healthcare professionals

Sponsorship statement:

This educational activity was funded by Novartis Pharmaceuticals UK Ltd; however the British Journal of Cardiology retained full editorial control, including the formulation of the agenda, contents and selection of speakers. The media partners for this activity are the British Journal of Cardiology and GPnotebook.

An assessment of new cholesterol targets. Measuring Lp(a): A ‘once in a lifetime’ opportunity

16 December 2025

Supported

Dr Julia Kenkre and Dr Holly Morgan explore the role of elevated lipoprotein(a) [Lp(a)] levels in cardiovascular risk, its measurement challenges, clinical implications, and the approach to management.

Speakers

Dr Holly Morgan, Clinical Lecturer and Interventional Cardiology Fellow, King’s College London
Dr Julia Kenkre, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Trust

Learning objectives

Why Lp(a) is gaining clinical importance, and how elevated Lp(a) levels can influence cardiovascular risk
Best practice for measuring Lp(a) levels including who should be tested and how results can guide management strategies